| pubmed-article:17933486 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17933486 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:17933486 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17933486 | lifeskim:mentions | umls-concept:C0033137 | lld:lifeskim |
| pubmed-article:17933486 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:17933486 | lifeskim:mentions | umls-concept:C0205216 | lld:lifeskim |
| pubmed-article:17933486 | lifeskim:mentions | umls-concept:C0086931 | lld:lifeskim |
| pubmed-article:17933486 | lifeskim:mentions | umls-concept:C1169989 | lld:lifeskim |
| pubmed-article:17933486 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:17933486 | pubmed:dateCreated | 2008-6-2 | lld:pubmed |
| pubmed-article:17933486 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:abstractText | Methadone treatment reduces human immunodeficiency virus (HIV) risk, but the effects of primary-care-based buprenorphine/naloxone on HIV risk are unknown. The purpose of this study was to determine whether primary-care-based buprenorphine/naloxone was associated with decreased HIV risk behavior. We conducted a longitudinal analysis of 166 opioid-dependent persons (129 men and 37 women) receiving buprenorphine/naloxone treatment in a primary care clinic. We compared baseline and 12- and 24-week overall, drug-related, and sex-related HIV risk behaviors using the AIDS/HIV Risk Inventory (ARI). Buprenorphine/naloxone treatment was associated with significant reductions in overall and drug-related ARI scores from baseline to 12 and 24 weeks. Intravenous drug use in the past 3 months was endorsed by 37%, 12%, and 7% of patients at baseline and at 12 and 24 weeks, respectively (p< .001). Sex while you or your partner were "high" was endorsed by 64%, 13%, and 15% of patients at baseline and at 12 and 24 weeks, respectively (p< .001). Inconsistent condom use during sex with a steady partner was high at baseline and did not change over time. We conclude that primary-care-based buprenorphine/naloxone treatment is associated with decreased drug-related HIV risk, but additional efforts may be needed to address sex-related HIV risk when present. | lld:pubmed |
| pubmed-article:17933486 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17933486 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17933486 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17933486 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17933486 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:17933486 | pubmed:issn | 0740-5472 | lld:pubmed |
| pubmed-article:17933486 | pubmed:author | pubmed-author:O'ConnorPatri... | lld:pubmed |
| pubmed-article:17933486 | pubmed:author | pubmed-author:FiellinDavid... | lld:pubmed |
| pubmed-article:17933486 | pubmed:author | pubmed-author:PantalonMicha... | lld:pubmed |
| pubmed-article:17933486 | pubmed:author | pubmed-author:SchottenfeldR... | lld:pubmed |
| pubmed-article:17933486 | pubmed:author | pubmed-author:MooreBrent... | lld:pubmed |
| pubmed-article:17933486 | pubmed:author | pubmed-author:ChawarskiMare... | lld:pubmed |
| pubmed-article:17933486 | pubmed:author | pubmed-author:SullivanLynn... | lld:pubmed |
| pubmed-article:17933486 | pubmed:author | pubmed-author:BarryDeclanD | lld:pubmed |
| pubmed-article:17933486 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17933486 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:17933486 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17933486 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17933486 | pubmed:pagination | 87-92 | lld:pubmed |
| pubmed-article:17933486 | pubmed:dateRevised | 2011-8-1 | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:meshHeading | pubmed-meshheading:17933486... | lld:pubmed |
| pubmed-article:17933486 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:17933486 | pubmed:articleTitle | Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. | lld:pubmed |
| pubmed-article:17933486 | pubmed:affiliation | Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. lynn.sullivan@yale.edu | lld:pubmed |
| pubmed-article:17933486 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17933486 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:17933486 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17933486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17933486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17933486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17933486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17933486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17933486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17933486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17933486 | lld:pubmed |
